Features of pathogenetic therapy of infectious and inflammatory diseases of the ENT organs

Infectious and inflammatory diseases of the ENT organs are the most common and usually have a viral etiology. Combined lesions are predominantly nasopharyngitis, pharyngotonsillitis, laryngotracheitis. Lesions of the nose and paranasal sinuses are often combined with otitis media. The onset of the disease is aggressive, with pronounced symptoms – impaired nasal breathing, rhinorrhea, cough, headache, etc. All this requires timely medical care of a wide range of action, capable of alleviating the patient’s suffering at an early stage. Analysis of literary data showed that timely treatment not only improves the clinical picture of the disease, but also prevents further spread of the infectious process and the development of complications. Such a drug is Respero Myrtol, an effective and safe herbal preparation obtained from essential oils of plants such as eucalyptus, lime and pine, mainly consisting of monoterpenes such as d-limonene, 1,8-cineole and alpha-pinene. It has been proven that it is not only well tolerated, but also a safe alternative to antibiotics for the treatment of respiratory infections with post-viral complications without the use of specific microbial agents. The high safety profile makes it suitable for both adults and pediatric practice. Thus, the use of herbal preparations has undoubted practical significance for the treatment of infectious and inflammatory diseases of the ENT organs. The use of such a natural remedy as Respero Myrtol is effective and safe both as monotherapy and in combination with other drugs. Its multifaceted action – improving mucus drainage, reducing inflammation, providing antioxidant protection and antimicrobial action – makes it a valuable therapeutic agent for the treatment of respiratory diseases.

1. Fürst R, Luong B, Thomsen J, Wittig T. ELOM-080 as Add-On Treatment for Respiratory Tract Diseases – A Review of Clinical Studies Conducted in China. Planta Med. 2019;85(9-10):745–754. https://doi.org/10.1055/a-0942-1993.

2. Serebryakova IYu, Garashchenko TI, Kuznetsov AO, Akhinyan AO. Application of mucosecretolytics of plant origin in otorhinolaryngology. Meditsinskiy Sovet. 2021;(6):133–137. (In Russ.) https://doi.org/10.21518/2079-701X-2021-6-133-137.

3. Лавренова ГВ, Глухова ЕЮ, Монгуш СЛ, Шишкунова ТМ, Митина АО, Тарасова МА. Фитотерапия в комплексном лечении вирусного воспаления ЛОР-органов. В: Блоцкий АА. (ред.). Актуальные вопросы оториноларингологии: материалы межрегиональной научно-практической конференции оториноларингологов Сибири и Дальнего Востока с международным участием. Благовещенск, 30 июня 2016 г. Благовещенск: Амурская государственная медицинская академия; 2016. C. 5–11. Режим доступа: https://elibrary.ru/wddoxt.

4. Gurov AV, Muzhichkova AV. Modern possibilities of herbal medicine in the treatment of acute inflammatory diseases of the upper respiratory tract. Meditsinskiy Sovet. 2021;(18):127–133. (In Russ.) https://doi.org/10.21518/2079-701X-2021-18-127-133.

5. Zaytseva OV. The role of mucolytic therapy in the treatment of sinobronchial syndrome. Vestnik Oto-Rino-Laringologii. 2012;77(2):63–65. (In Russ.) Available at: https://www.mediasphera.ru/issues/vestnik-otorinolaringologii/2012/2/030042-46682012214.

6. Njoroge GN, Bussmann RW. Traditional management of ear, nose and throat (ENT) diseases in Central Kenya. J Ethnobiol Ethnomed. 2006;2:54. https://doi.org/10.1186/1746-4269-2-54.

7. Asher BF, Seidman M, Snyderman C. Complementary and alternative medicine in otolaryngology. Laryngoscope. 2001;111(8):1383–1389. https://doi.org/10.1097/00005537-200108000-00013.

8. Herbal medicines against respiratory diseases – traditional empiricism or pharmacological evidence? Med Monatsschr Pharm. 2014;37(11):394–399. Available at: https://pubmed.ncbi.nlm.nih.gov/25632601/.

9. Paparoupa M, Gillissen A. Is Myrtol® Standardized a New Alternative toward Antibiotics? Pharmacogn Rev. 2016;10(20):143–146. https://doi.org/10.4103/0973-7847.194045.

10. Riazantsev SV, Artyushkin SA, Budkovaya MA. The place of mucoactuve therapy of rhinosinisitis in the international and Russian guidelines. Vestnik Oto-Rino-Laringologii. 2015;80(4):81–84. (In Russ.) https://doi.org/10.17116/otorino201580481-84.

11. Selezneva LV, Vartanyan KG. Using of herbal mucolytics in the complex therapy of acute and chronic rhinosinusitis. Meditsinskiy Sovet. 2023;17(7):176–181. (In Russ.) https://doi.org/10.21518/ms2023-032.

12. Gottschlich S, Röschmann K, Candler H. Phytomedicines in Acute Rhinosinusitis: A Prospective, Non-interventional Parallel-Group Trial. Adv Ther. 2018;35(7):1023–1034. https://doi.org/10.1007/s12325-018-0736-7.

13. Mashkova TA, Maltsev AB. Selective prophylaxis of rhino-sinusitis in children with acute respiratory viral infection. Current Pediatrics. 2012;11(2):106–108. (In Russ.) https://doi.org/10.15690/vsp.v11i2.220.

14. Prall S, Bowles EJ, Bennett K, Cooke CG, Agnew T, Steel A, Hausser T. Effects of essential oils on symptoms and course (duration and severity) of viral respiratory infections in humans: A rapid review. Adv Integr Med. 2020;7(4):218–221. https://doi.org/10.1016/j.aimed.2020.07.005.

15. Svistushkin VM, Mokoyan ZhT, Babaeva AE. Acute bacterial sinusitis: current concepts in antibiotic therapy. Meditsinskiy Sovet. 2023;17(7):14–19. (In Russ.) https://doi.org/10.21518/ms2023-065.

16. Han D, Wang N, Zhang L. The effect of myrtol standardized on human nasal ciliary beat frequency and mucociliary transport time. Am J Rhinol Allergy. 2009;23(6):610–614. https://doi.org/10.2500/ajra.2009.23.3401.

17. Jund R, Mondigler M, Stammer H, Stierna P, Bachert C. Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis. Acta Otolaryngol. 2015;135(1):42–50. https://doi.org/10.3109/00016489.2014.952047.

18. Li YY, Liu J, Li CW, Subramaniam S, Chao SS, Yu FG et al. Myrtol standardized affects mucociliary clearance. Int Forum Allergy Rhinol. 2017;7(3):304–311. https://doi.org/10.1002/alr.21878.

19. Perić A, Soklič Košak T, Aleksić A, Kopacheva-Barsova G, Perić AV. Efficacy and Safety of Myrtol® Standardized in the Treatment of Acute and Chronic Rhinosinusitis: A Review of Literature. Erciyes Med J. 2021;43(1):3–8. https://doi.org/10.14744/etd.2020.34467.

20. Koch AK, Klose P, Lauche R, Cramer H, Baasch J, Dobos GJ, Langhorst J. A Systematic Review of Phytotherapy for Acute Rhinosinusitis. Forsch Komplementmed. 2016;23(3):165–169. (In German) https://doi.org/10.1159/000447467.

21. Rantzsch U, Vacca G, Dück R, Gillissen A. Anti-inflammatory effects of Myrtol standardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease. Eur J Med Res. 2009;14(Suppl. 4):205–209. https://doi.org/10.1186/2047-783X-14-S4-205.

22. Taw MB, Nguyen CT, Wang MB. Complementary and integrative treatments: rhinosinusitis. Otolaryngol Clin North Am. 2013;46(3):345–366. https://doi.org/10.1016/j.otc.2013.02.002.

23. Cohen R, Haas H, Lorrot M, Biscardi S, Romain O, Vie Le Sage F et al. Antimicrobial treatment of ENT infections. Arch Pediatr. 2017;24(12S):S9–S16. https://doi.org/10.1016/S0929-693X(17)30512-2.

24. Begrow F, Böckenholt C, Ehmen M, Wittig T, Verspohl EJ. Effect of myrtol standardized and other substances on the respiratory tract: ciliary beat frequency and mucociliary clearance as parameters. Adv Ther. 2012;29(4):350–358. https://doi.org/10.1007/s12325-012-0014-z.

25. Karpova EP, Tulupov DA, Emel’yanova MP. Use of Myrtol standardized in the treatment of children with acute rhinosinusitis. Vestnik Oto-Rino-Laringologii. 2016;81(1):47–50. (In Russ.) https://doi.org/10.17116/otorino201681147-50.

26. Kastyro IV, Muradov GM, Popadyuk VI, Kalmykov IK, Mikhalskaia PV, Saveleva NA et al. An integrated approach to the rehabilitation of patients after septoplasty in the early postoperative period. Head and Neck. Russian Journal. 2022;10(2, Suppl. 1):21–27. (In Russ.) Available at: https://hnj.science/kompleksnyj-podxod-k-reabilitacii-pacientov-posle-septoplastiki-v-rannem-posleoperacionnom-periode/.

27. Hashigucci K, Matsunobu T. Etiology of acute pharyngitis in adults: the presence of viruses and bacteria. Nihon Jibiinkoka Gakkai Kaiho. 2003;106(5):532–539. (In Japanese) https://doi.org/10.3950/jibiinkoka.106.532.

28. Matthys H, de Mey C, Carls C, Ryś A, Geib A, Wittig T. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. Arzneimittelforschung. 2000;50(8):700–711. https://doi.org/10.1055/s-0031-1300276.

29. Scasso F, Ferrari G, DE Vincentiis GC, Arosio A, Bottero S, Carretti M et al. Emerging and re-emerging infectious disease in otorhinolaryngology. Acta Otorhinolaryngol Ital. 2018;38(Suppl. 1):S1–S106. https://doi.org/10.14639/0392-100X-suppl.1-38-2018.

30. Zhao DY, Qu HJ, Guo JM, Zhao HN, Yang YY, Zhang P et al. Protective Effects of Myrtol Standardized Against Radiation-Induced Lung Injury. Cell Physiol Biochem. 2016;38(2):619–634. https://doi.org/10.1159/000438655.

31. Red G. Good evidence for phytotherapy drugs. MMW Fortschr Med. 2015;157(7):72. (In German) https://doi.org/10.1007/s15006-015-2978-5.

32. Zhao TT, Zhu LL, Chen M, Zhou Q. Is it appropriate regarding patient preference to take Myrtol standardized enteric-coated soft capsules after a meal rather than at fasted state? A food-drug pharmacokinetic interaction study in healthy Chinese volunteers. Patient Prefer Adherence. 2016;10:2031–2037. https://doi.org/10.2147/PPA.S116823.

33. Duan Q, Du Y. Eustachian tube dysfunction misdiagnosed: a case report. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;29(17):1573. (In Chinesе) Available at: https://pubmed.ncbi.nlm.nih.gov/26647551/.

34. He J, Wu P, Wu S, Yu SF, Li MR, Liao L et al. Study on the preventive effect of the myrtol forte from secretory otitis media in patients with nasopharyngeal carcinoma after radiotherapy. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013;27(10):473–474. (In Chinese) Available at: https://pubmed.ncbi.nlm.nih.gov/23937010/.

35. Zhang J, Zhong Z, Xiao S, Liu Y, Zhen Z, Ren L, Zhang L. Tubomanometry value as an associated factor for medication outcomes in adult acute otitis media with effusion. Eur Arch Otorhinolaryngol. 2018;275(1):53–57. https://doi.org/10.1007/s00405-017-4772-8.